CRTO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CRTO is not a good buy right now for a Beginner long-term investor, especially with $50,000-$100,000 to deploy. The stock has weak technical momentum, disappointing latest-quarter fundamentals, and recent analyst revisions are trending lower. While valuation may become attractive if earnings stabilize and the agentic commerce opportunity develops, the current setup is more suitable for waiting than buying immediately. Based on the data provided, my direct opinion is to hold off for now.
CRTO's trend is bearish. The MACD histogram is negative and still expanding lower, which shows downside momentum remains in place. RSI_6 at 30.59 is near oversold but not yet a strong reversal signal. The moving average structure is bearish with SMA_200 > SMA_20 > SMA_5, indicating the stock is still trading below a healthier trend. Price at 16.42 is near S1 support at 16.395 and above S2 at 15.261, so the stock is testing support rather than confirming a rebound. Overall, the chart does not yet support an immediate long-term buy.
["Q1 revenue came in above expectations at $425 million.", "Analysts such as Benchmark, Stifel, Citi, Bernstein, JPMorgan, and BMO still have at least some positive ratings on the name, with several Buy/Outperform views remaining.", "BMO highlighted the agentic commerce opportunity and service trial as a possible future revenue driver.", "Stock pattern data suggests a modest positive near-term drift after the recent setup."]
["Q1 2026 revenue fell 5.94% year over year, showing contracting top-line growth.", "Net income dropped 79.39% year over year and EPS fell 77.27%, signaling sharp profitability deterioration.", "Free cash flow declined 65% according to the news summary.", "Wells Fargo downgraded the stock to Equal Weight and cut its target sharply to $18 from $34 after Q1 results and weaker Q2/full-year guidance.", "Several analysts lowered price targets in recent months, showing a downward trend in Street expectations.", "Technical indicators remain bearish, with negative MACD momentum and weak moving average alignment."]
Latest quarter: Q1 2026. Revenue was $424.6 million, down 5.94% year over year. Net income was $7.8 million, down 79.39% year over year. EPS fell 77.27% year over year to 0.15. Gross margin was 52.45%, slightly lower year over year. The quarter shows weaker growth and much lower profitability, which is not ideal for a beginner-focused long-term buy.
Analyst sentiment has weakened recently. Wells Fargo downgraded CRTO to Equal Weight and cut its target from $34 to $18, citing weaker guidance and added U.S. customer issues. Benchmark still has a Buy rating but reduced its target to $25 from $30. Stifel, Citi, Bernstein, JPMorgan, Morgan Stanley, and BMO all lowered targets in recent updates, though several maintained Buy/Outperform ratings. The pros view is that the stock still has strategic optionality and some analysts remain constructive; the cons view is that earnings growth has weakened, guidance was cut, and targets are moving down across the Street.
